- Home
- HFBL vs IMA Comparison
HFBL vs IMA Comparison
Compare HFBL & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HFBL | IMA |
|---|---|---|
| Founded | 1924 | 2019 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.9M | 66.3M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | HFBL | IMA |
|---|---|---|
| Price | $22.00 | $5.94 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 2.0K | ★ 9.6K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | ★ 7.69 | N/A |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $1,303,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.77 | ★ N/A |
| Revenue Growth | ★ 17.49 | N/A |
| 52 Week Low | $12.83 | $3.94 |
| 52 Week High | $24.00 | $17.50 |
Technical Indicators
Market Signals| Indicator | HFBL | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 65.37 | 54.83 |
| Support Level | $19.95 | $5.36 |
| Resistance Level | N/A | $6.08 |
| Average True Range (ATR) | 0.51 | 0.28 |
| MACD | 0.19 | 0.00 |
| Stochastic Oscillator | 55.56 | 71.19 |
Price Performance
Historical ComparisonAbout HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.